News

Enlarge image

ResearchAustriaGermanySwitzerland

New approach resets MS

06.06.2013 - An international research team has found a way to calm the autoimmune reaction that leads to myelin destruction in Multiple Sclerosis patients.

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and reduced patients' immune system reactivity to myelin by 50 to 75 percent. In 9 patients, the researchers from Hamburg, Vienna, Zürich, and Chicago succeeded to reduce the autoimme reaction against myelin, which surrounds neurons like an insulator. They did so by coupling 7 myelin antigens thought to induce MS to the patients’ white blood cells ex vivo, which induced immune tolerance after reinjection in their bloodstream. Most of the patients who received high doses of the antigen-coupled blood cells did not show any new brain lesions or symptomatic relapses up to the end of the study’s six month follow-up period (Science Translat. Medicine, 5 May, 2013).

"The therapy stops autoimmune responses that are already activated and prevents the activation of new autoimmune cells," said co-author Stephen Miller from Northwestern University Feinberg School of Medicine. "Our approach leaves the function of the normal immune system intact. That's the holy grail." According to lead author Andreas Lutterotti from Innsbruck Medical University/Medical Center Hamburg-Eppendorf, the dead lymphocytes carrying the myelin antigens are filtered out of the blood in the spleen. During this process, immune cells start to recognise the myelin antigens as harmless and immune tolerance quickly develops. They confirmed this in patients by immune assays.

Although the patient numbers are small in this first-in-human study, the safety, feasibility, and early results suggest that this approach may provide a promising avenue for future trials. Unlike current immunosuppressive drugs for MS, the new approach does not compromise the immune system’s infection-fighting abilities. The process mimics a natural process by which millions of red and white blood cells, which normally die each day, are cleared from the bloodstream without alerting the immune system.  

The human safety study sets the stage for a phase 2 trial to see if the new treatment can prevent the progression of MS in humans. Scientists are currently trying to raise $1.5 million to launch the trial, which has already been approved in Switzerland. The new approach may be useful for treating not only MS but also a host of other autoimmune and allergic diseases simply by switching the antigens attached to the cells.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/new-approach-resets-ms.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.25 EUR5.00%
  • SCANCELL HOLDINGS (UK)18.25 GBP4.29%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • IMMUPHARMA (UK)25.50 GBP-12.07%

TOP

  • EPIGENOMICS (D)4.46 EUR109.4%
  • VERONA PHARMA (UK)3.40 GBP28.3%
  • WILEX (D)2.09 EUR19.4%

FLOP

  • PROTHENA PLC (IE)34.27 USD-39.1%
  • PLETHORA (UK)2.75 GBP-33.3%
  • BIONOR PHARMA (N)0.88 NOK-30.2%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 06.02.2016